SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (7651)1/3/2003 11:45:43 AM
From: Biomaven  Read Replies (1) of 52153
 
A very strong sales performance from FRX here. I predict that Lexapro will end up as the best-selling antidepressant. What's been most encouraging is that a good chunk of the Lexapro sales have not just been cannibalized Celexa sales.

What's also interesting is that generic Prozac has not hurt the other brand name SSRI's. This is what I had predicted - you just don't get doctors switching to a different generic in the same class simply because it is cheaper. In fact, the lack of detailing for Prozac has probably helped the other drugs in this class.

Whether the same will hold true for the non-sedating antihistamines remains to be seen. Two big differences - Claritin is OTC not generic (makes it less of a threat in my view), but there is less differences between the drugs in the class (so switching is easier). Ultimately it may be reimbursement issues that will drive this.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News